Summary
GlobalData, the industry analysis specialist, has released a new report on the Pharmaceutical and Healthcare industry, "Type 1 Diabetes-Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global type 1 diabetes market. The report identifies the key trends shaping and driving the global type 1 diabetes market, a key segment within the pharma industry. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global type 1 diabetes sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope
The scope of the report includes:
-Annualized global type 1 diabetes market revenues data from 2000 to 2009, forecast forward for 7 years to 2016.
-Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
-Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
-Analysis of the current and future market competition in the global type 1 diabetes market. Key market players include Novo Nordsik, Eli Lilly, GlaxoSmithKline and Sanofi-aventis.
-Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with type 1 diabetes.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global type 1 diabetes market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global type 1 diabetes market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective   counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global type 1 diabetes market landscape? -Identify, understand and capitalize.

Table of Contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Type 1 Diabetes Therapeutics Market: Market Characterization 6
2.1 Overview 6
2.2 Type 1 Diabetes Market Size 6
2.3 Type 1 Diabetes Therapeutics Market Forecast and CAGR 7
2.4 Drivers and Barriers for the Type 1 Diabetes Therapeutics Market 8
2.4.1 Drivers for the Type 1 Diabetes Therapeutics Market 8
2.4.2 Restraints for the Type 1 Diabetes Therapeutics Market 9
2.5 Opportunity and Unmet Need 10
2.6 Key Takeaway 11
3 Type 1 Diabetes Therapeutics Market: Competitive Assessment 12
3.1 Overview 12
3.2 Strategic Competitor Assessment 12
3.3 Product Profile for the Major Marketed Products in the Type 1 Diabetes Disease Market 13
3.3.1 Lantus (Insulin Glargine) 13
3.3.2 Humulin (Human Insulin) 16
3.3.3 Humalog (Insulin Lispro) 17
3.3.4 Novolog (Insulin Aspart) 19
3.3.5 Novolin (Human Insulin) 20
3.3.6 Apidra (Insulin Glulisine) 21
3.3.7 Levemir (Insulin Detemir) 23
3.4 Key Takeaway 24
4 Type 1 Diabetes Therapeutics Market: Pipeline Assessment 25
4.1 Overview 25
4.2 Strategic Pipeline Assessment 25
4.2.1 Technology Trends Analytic Framework 25
4.3 Type 1 Diabetes Therapeutics-Promising Drugs under Clinical Development 26
4.4 Molecule Profile for Promising Drugs under Clinical Development 27
4.4.1 rhGAD65 (Diamyd) 27
4.4.2 DiaPep277 27
4.4.3 Otelixizumab 28
4.4.4 Oral-lyn 28
4.5 Type 1 Diabetes Therapeutics Market-Clinical Pipeline by Mechanism of Action 29
4.6 Type 1 Diabetes Pipeline-Pipeline by Clinical Phases of Development 31
4.6.1 Type 1 Diabetes Therapeutics-Filed and Approved Drugs 31
4.6.2 Type 1 Diabetes Therapeutics-Phase III Clinical Pipelinea 32
4.6.3 Type 1 Diabetes Therapeutics-Phase II Clinical Pipeline 33
4.6.4 Type 1 Diabetes Therapeutics-Phase I Clinical Pipeline 34
4.6.5 Type 1 Diabetes Therapeutics-Phase I Clinical Pipeline 34
4.7 Key Takeaway 35
5 Type 1 Diabetes Market: Implications for Future Market Competition 36
6 Type Diabetes Therapeutics Market: Future Players in the Type 1 Diabetes Therapeutics Market 38
6.1 Introduction 38
6.2 Novo Nordisk 38
6.2.1 Business Description 38
6.2.2 Metabolic Disorders Portfolio 39
6.2.3 Type 1 Diabetes Pipeline Portfolio 40
6.3 GlaxoSmithKline 41
6.3.1 Business Description 41
6.3.2 Metabolic Disorders Portfolio 42
6.3.3 Type 1 Diabetes Pipeline Portfolio 42
6.4 Eli Lilly 43
6.4.1 Business Description 43
6.4.2 Metabolic Disorders Portfolio 44
6.4.3 Type 1 Diabetes Pipeline Portfolio 44
6.5 Sanofi-aventis 45
6.5.1 Business Description 45
6.5.2 Metabolic Disorders Portfolio 46
6.5.3 Type 1 Diabetes Pipeline Portfolio 46
7 Type 1 Diabetes Therapeutics Market: Appendix 47
7.1 Definitions 47
7.2 Abbreviations 47
7.3 Research Methodology 48
7.3.1 Coverage 48
7.3.2 Secondary Research 49
7.3.3 Forecasting 49
7.3.4 Primary Research 51
7.3.5 Expert Panel Validation 52
7.4 Contact Us 52
7.5 Disclaimer 52
7.6 Sources 52

List of Tables
1.1 List of Tables
Table 1: Type 1 Diabetes Therapeutics Market, Global, Revenues ($bn), 2001-2009 7
Table 2: Type 1 Diabetes Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2016 8
Table 3: Type 1 Diabetes Therapeutics Market, Lantus, Clinical Studies Outcome for Efficacy 14
Table 4: Type 1 Diabetes Therapeutics Market, Lantus, Adverse Events in 28-Week Clinical Trials of Adults and Children With Type 1 Diabetes 15
Table 5: Type 1 Diabetes Therapeutics Market, Lantus, Clinical Studies Outcome for Safety 15
Table 6: Humulin-Glycemic Parameters at the End of Treatment Period in Randomized Patients in Three Months Cross-Over Studies for Type 1 Diabetes 16
Table 7: Humulin-Results of Three Months Cross-Over Studies comparing Humulin with Humalog in Type 1 Diabetes 17
Table 8: Type 1 Diabetes Therapeutics Market, Humalog, Glycemic Parameters at the End of Treatment Period in Randomized Patients in Three Months Cross-Over Studies 18
Table 9: Humalog-Results of a Two Month Study Comparing the Use of Humalog and Humulin With Sulfonyluria (SU) Therapy 19
Table 10: Type 1 Diabetes Therapeutics Market, Novolog, Glycemic Parameters at the End of 24 Weeks Study 20
Table 11: Apidra-Efficacy Result of 26-Week Study Comparing Apidra with Insulin Lispro 22
Table 12: Apidra-Efficacy Result of 26-Week Study Comparing Apidra with Regular Insulin 22
Table 13: Apidra-Adverse Reactions Observed in Pooled Studies in Type 1 Diabetes Adults 22
Table 14: Levemir-Efficacy Result in 16-Week Non Blinded Study 23
Table 15:  Major Marketed Products Comparison in the Type 1 Diabetes Therapeutics Market, 2010 24
Table 16:  Type 1 Diabetes Therapeutics-Most Promising Drugs Under Clinical Development, 2010 26
Table 17: Type 1 Diabetes Therapeutics-Filed and Approved Drugs, 2010 31
Table 18: Type 1 Diabetes Therapeutics-Phase III Clinical Pipeline, 2010 32
Table 19: Type 1 Diabetes Therapeutics-Phase II Clinical Pipeline, 2010 33
Table 20: Type 1 Diabetes Therapeutics-Phase I Clinical Pipeline, 2010 34
Table 21: Type 1 Diabetes Therapeutics-Preclinical-Discovery Pipeline, 2010 34
Table 22:  Genzyme-Metabolic Disorders Marketed Products, 2010 39
Table 23: Novo Nordisk-Metabolic Disorders Pipeline Products, 2010 40
Table 24:  GlaxoSmithKline-Metabolic Disorders Marketed Products, 2010 42
Table 25: GlaxoSmithaKline-Metabolic Disorders Pipeline Products, 2010 42
Table 26: Eli Lilly-Metabolic Disorders Marketed Products, 2010 44
Table 27: Eli Lilly-Metabolic Disorders Pipeline Products, 2010 44
Table 28: Sanofi-aventis-Metabolic Disorders Marketed Products, 2010 46
Table 29: Sanofi-aventis-Metabolic Disorders Pipeline Products, 2010 46

List of Figures
1.2 List of Figures
Figure 1: Type 1 Diabetes Therapeutics Market, Global, Revenues ($bn), 2001-2009 7
Figure 2: Type 1 Diabetes Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2016 8
Figure 3:  Opportunity and Unmet Need in the Type 1 Diabetes Therapeutics Market, 2010 10
Figure 4:  Strategic Competitor Assessment of the Major Marketed Products in Type 1 Diabetes Therapeutics, 2010 13
Figure 5:  Technology Trends Analytic Framework of the Type 1 Diabetes Therapeutics Pipeline, 2010 25
Figure 6:  Technology Trends Analytic Framework  of the Type 1 Diabetes Therapeutics Pipeline-Description, 2010 26
Figure 7:  Type 1 Diabetes Therapeutics Market-Clinical Pipeline by Mechanism of Action, 2010 30
Figure 8:  Type 1 Diabetes Therapeutics Pipeline by Phase of Clinical Development, 2010 31
Figure 9:  Implications for Future Market Competition in the Type 1 Diabetes Market, 2010 36
Figure 10:  Type 1 Diabetes Therapeutics Market-Clinical Pipeline by Company, 2010 38
Figure 11:  GlobalData Methodology 48
Figure 12:  GlobalData  Market Forecasting Model 51